Market revenue in 2023 | USD 4,385.8 million |
Market revenue in 2030 | USD 5,722.3 million |
Growth rate | 3.9% (CAGR from 2023 to 2030) |
Largest segment | Subunit vaccines |
Fastest growing segment | Subunit Vaccines |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Subunit Vaccines, Inactivated, Live Attenuated, MRNA vaccines, Viral vector vaccines |
Key market players worldwide | Serum Institute of India Pvt. Ltd., CSL Ltd, Sanofi SA, GSK PLC, Merck & Co Inc, Pfizer Inc, Sinovac Biotech Ltd, BioNTech SE ADR, AstraZeneca PLC, Moderna Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to vaccine market will help companies and investors design strategic landscapes.
Subunit vaccines was the largest segment with a revenue share of 34.12% in 2023. Horizon Databook has segmented the Germany vaccine market based on subunit vaccines, inactivated, live attenuated, mrna vaccines, viral vector vaccines covering the revenue growth of each sub-segment from 2018 to 2030.
Presence of research institutions and leading vaccine manufacturers is propelling the Germany vaccine market. In addition, a surge in R&D activities and various strategic initiatives undertaken by leading participants are factors propelling market expansion. Moreover, in November 2022, BioNTech SE & Pfizer, Inc. initiated a phase I trial for a single-dose mRNA-based combination vaccine candidate for COVID-19 and influenza.
In addition, in May 2021, Bavarian Nordic A/S established a collaboration with Dynavax Technologies Corporation, a biopharmaceutical firm dedicated to creating and promoting innovative vaccines. This partnership aims to facilitate the marketing and distribution of HEPLISAV B [Hepatitis B Vaccine (Recombinant), Adjuvanted] in Germany.
This proves that Germany is one of the leading research locations, wherein several pharmaceutical & biotechnological companies focus on developing therapies for conditions such as cancer, cardiovascular disorders, & metabolic diseases and applications like drug formulation & development.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany vaccine market , including forecasts for subscribers. This country databook contains high-level insights into Germany vaccine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account